Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 247NETWORK 8OTHER_GOV 3FED 3INDUSTRY 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Methods × Clear all
NCT03152526 2020-07-09

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Miltenyi Biomedicine GmbH

Phase NA Terminated
1 enrolled 5 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01219192 2010-10-28

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Protgen Ltd

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡